William J. Peters - Nov 14, 2023 Form 4 Insider Report for Amphastar Pharmaceuticals, Inc. (AMPH)

Role
CFO, EVP & Treasurer, Director
Signature
/s/ William J Peters
Stock symbol
AMPH
Transactions as of
Nov 14, 2023
Transactions value $
-$2,373,447
Form type
4
Date filed
11/16/2023, 04:05 PM
Previous filing
Sep 8, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMPH Common Stock Options Exercise $430K +21.3K +20.96% $20.23 123K Nov 14, 2023 Direct
transaction AMPH Common Stock Options Exercise $495K +38K +30.99% $13.03 161K Nov 14, 2023 Direct
transaction AMPH Common Stock Sale -$779K -14.2K -8.85% $54.76 146K Nov 14, 2023 Direct F1, F2
transaction AMPH Common Stock Sale -$1.68M -30.2K -20.6% $55.67 116K Nov 14, 2023 Direct F1, F3
transaction AMPH Common Stock Sale -$841K -14.9K -12.79% $56.53 101K Nov 14, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMPH Employee Stock Option (right to buy) Options Exercise $0 -21.3K -58.26% $0.00 15.2K Nov 14, 2023 Common Stock 21.3K $20.23 Direct F5
transaction AMPH Employee Stock Option (right to buy) Options Exercise $0 -38K -54.99% $0.00 31.1K Nov 14, 2023 Common Stock 38K $13.03 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.15 to $55.145, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.16 to $56.15, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.17 to $56.81, inclusive.
F5 Shares subject to the option are fully vested and immediately exercisable.